Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cigall Kadoch
Beth Israel Deaconess Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Foghorn Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kadoch is a co-founder of Foghorn Therapeutics, a small biotech company. Foghorn has developed a “Gene Traffic Control” platform, based on the biology of the chromatin regulatory system, to develop therapeutics targeting epigenetic regulators in cancer and other diseases.This grant aims to (1) comprehensively profile the assembly and modular organization of PBAF complexes and define the impact of PBRM1; and to (2) define the consequences of PBRM1 loss on the recruitment of RNA Pol II to active promoters and transcription initiation. The DFCI Conflict of Interest Committee concluded that the results of this research could be of scientific and financial interest to Foghorn Therapeutics and, accordingly, represented a financial conflict of interest under the regulations.
DF/HCC Kidney Cancer SPORE
This SPORE is focused on several important themes in kidney cancer: 1) using the growing understanding of kidney cancer biology to target critical pathways and produce durable clinical benefit for patients with advanced kidney cancer; 2) correlating genomic analyses with clinical outcomes to identify molecular biomarkers for the purposes of monitoring and predicting treatment outcome; 3) understanding the mechanisms by which kidney cancer becomes resistant to standard therapies and developing effective treatment combinations.
Filed on May 24, 2019.
Tell us what you know about Cigall Kadoch's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Cigall Kadoch”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $200,000 - $249,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $150,000 - $199,999 |
| Cigall Kadoch | Sarc | Conflict of Interest | Dana-Farber Cancer Institute | $150,000 - $199,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | $150,000 - $199,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.